While fears of quality had previously slowed the transition to virtual trials, Christian noted that these fears have proven to be unfounded.
Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study
September 7, 2022
The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.